Related Experiment Video
Updated: Jul 5, 2026
09:51
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
Published on: December 4, 2023
[Retroperitoneal sarcomas: a single center experience]
Ben Hassouna J1, Slimane M, Damak T
1Service de chirurgie carcinologique, institut Salah Azaïz, boulevard 9-Avril-1938-Bab-Saadoun, Tunis 1006, Tunisie.
Summary
Retroperitoneal soft tissue sarcomas have a poor prognosis, with low survival rates. A higher mitotic index significantly impacts patient survival, suggesting a need for more aggressive treatment strategies.
Area of Science:
- Oncology
- Surgical Pathology
- Sarcoma Research
Context:
- Retroperitoneal soft tissue sarcomas are rare and aggressive tumors.
- Management and clinical outcomes for these sarcomas are often challenging.
- Limited data exists on prognostic factors influencing survival in retroperitoneal sarcomas.
Purpose:
- To analyze the management and clinical outcomes of patients treated for retroperitoneal soft tissue sarcoma.
- To identify significant prognostic factors affecting survival in this patient cohort.
Summary:
- This retrospective study analyzed 20 adult patients (1980-2000) with retroperitoneal soft tissue sarcomas (7 liposarcomas, 13 leiomyosarcomas).
- Mean tumor size was 26 cm, with most patients undergoing incomplete resection (R1/R2).
- Overall survival rates were 45% at two years and 10% at five years. Only mitotic index (scale 1,2 vs. 3) significantly influenced survival (p=0.02).
Impact:
- This study highlights the generally poor outcomes for retroperitoneal sarcoma patients.
- Survival rates are notably low compared to other studies.
- Findings suggest that a more aggressive therapeutic approach may be warranted.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...